Company Overview and News
The proposed merger comes a year after the entry of an entity called ACE Investment Bank into Apex. The entity emerged with a 23% stake in Apex at about the time when a similar sized block was traded off market by the late Chan Guan Seng(pic), Apex’s former executive chairman and parties close to him. The share price of Apex then was around RM2 a piece.
4898 1155 1023 1015 MLYBY MLYNF 5088 AMMHF CIMDF
Banking sector Maintain neutral: The negative surprise in banks’ financial results for second quarter of 2018 (2Q18) was the 1.5% year-on-year (y-o-y) drop in operating revenues. At the top line, net interest incomes slid by 3.1% y-o-y in 2Q18 under the pressure of margin contraction arising from stiff competition for deposits. Also, non-interest incomes fell by 9.2% y-o-y in 2Q18, owing to lower investment incomes and weak expansion in fee incomes.
1015 PBLOF AMMHF 1295
“Malaysian banks’ second-quarter net profit was below our expectations as two banks, namely, Public Bank Bhd and Affin Bank Bhd, missed our forecasts, compared with only one bank (AMMB Holdings Bhd) that outperformed our expectations. “The deviation from our forecast came mainly from lower-than-expected topline growth and the unexpected surge in Affin’s LLP.” While loan growth improved in 2Q18, CGSCIMB is projecting a slowdown in 4Q18.
1015 PBLOF AMMHF 1295
AABAR Investments PJS’ move to place out 120.3 million of its shares in RHB Bank Bhd two weeks ago — the equivalent of about a 3% stake — was likely to test the market’s appetite for potentially more paring down of its holding in the future, according to sources.
RHBAF 1015 AMMHF 1066
KUALA LUMPUR: Malaysian banks reported earnings that were largely in line with analysts’ expectations for the April to June quarter (2Q) and are cautiously optimistic that loan growth, subdued so far, will pick up later in the year.
1155 1023 1015 5258 PBLOF MLYBY MLYNF 5819 AMMHF 1295 CIMDF
KUALA LUMPUR (Aug 27): The Minority Shareholder Watch Group (MSWG) will include financially distressed companies and China-based companies listed on Bursa Malaysia on its radar by June next year, from 300 listed firms currently.
MLYNF 7113 8621 TPGVF AMMHF 1023 5347 TNABY SMEBF AXXTF MYTEF PNAGF 5183 MLYBY PECGF 4197 6399 5681 6033 CIMDF TGLVY 1155 PNADF 4588 1015 4863 6888 TNABF BSMAF 1818
AMMB Holdings Bhd (+ve) TRADING of shares in AMMB Holdings Bhd (fundamental: 1/3, valuation: 2.25/3), triggered our proprietary momentum algorithm yesterday for the first time this year. The stock closed 15 sen or 3.8% higher at RM4.15, with a market capitalisation of RM12.51 billion.
KUALA LUMPUR (Aug 23): AMMB Holdings Bhd (AmBank) shares rose as much as 11 sen or 2.8% to RM4.11 so far today after the financial services group reported on Tuesday that net profit increased to RM347.59 million in the first quarter ended June 30, 2018 (1QFY19) from RM328.27 million a year earlier.
KUALA LUMPUR: Versatile Creative Bhd , AMMB Holdings Bhd , Sunway Bhd , Paramount Corp Bhd, Ranhill Holdings Bhd and MCT Bhd are among the stocks to watch on Thursday, according to JF Apex Research.
4995 1015 AMMHF 5272
KUALA LUMPUR (Aug 20): Based on corporate announcements and news flow today, companies that will be in focus on Thursday (Aug 23) may include: Sime Darby Plantation Bhd, Petronas Chemicals Group Bhd, Eastern & Oriental Bhd, MCT Bhd, Taliworks Corp, Ranhill Holdings Bhd, Versatile Creative Bhd, AMMB Holdings Bhd, Sunway Bhd and Paramount Corp Bhd.
4995 1015 5183 PECGF AMMHF 5272
KUALA LUMPUR (Aug 21): AMMB Holdings Bhd's (AmBank Group) net profit rose 5.9% to RM347.59 million in the first financial quarter ended June 30, 2018 (1QFY19) from RM328.27 million a year ago, supported by higher net interest income (NII).
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...